ANGIOTENSIN II RECEPTOR BLOCKER COMBINED WITH CALCIUM CHANNEL BLOCKER IS MORE EFFECTIVE IN REDUCTION OF BLOOD PRESSURE VARIABILITY THAN COMBINED WITH DIURETICS
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Eun Joo | - |
dc.contributor.author | Lee, Hae Young | - |
dc.contributor.author | Sung, Ki Chul | - |
dc.contributor.author | Park, Sungha | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Choi, Dong-Ju | - |
dc.contributor.author | Ha, Jong Won | - |
dc.contributor.author | Ahn, Young Keun | - |
dc.contributor.author | Shin, Jinho | - |
dc.contributor.author | Hong, Soon-Jun | - |
dc.contributor.author | Kim, Soon Kil | - |
dc.contributor.author | Chung, Wook-Jin | - |
dc.contributor.author | Yoo, Byung Su | - |
dc.contributor.author | Hong, Taek Jong | - |
dc.contributor.author | Youn, Ho Joong | - |
dc.contributor.author | Cho, Myeong-Chan | - |
dc.contributor.author | Chae, Shung Chull | - |
dc.contributor.author | Kim, Young Jo | - |
dc.contributor.author | Kim, Chong-Jin | - |
dc.date.accessioned | 2021-08-03T06:08:57Z | - |
dc.date.available | 2021-08-03T06:08:57Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2016-09-24 | - |
dc.identifier.issn | 0263-6352 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/35479 | - |
dc.description.abstract | Objective: Hypertensive patients with greater blood pressure variability (BPV) are associated with a higher rate of cardiovascular events. We compared the efficacy of angiotensin II receptor blocker (ARB)/calcium-channel blocker combination with ARB/diuretic combination in reduction of 24-hour BPV. Design and Method: In a prospective, randomized, double-blind trial, hypertensive patients were assigned to Losartan/Amlodipine (L/A, dose of 50 mg/5 mg or 100 mg/5 mg) group or Losartan/Hydrochlorothiazide (L/H, dose of 50 mg/12.5 mg or 100 mg/25 mg) group. 24-hour ambulatory BP was measured at baseline and after 20 weeks treatment. BPV was calculated from weighted standard deviation and compared between two groups. Results: Total 220 patients [mean age = 59.6 ± 12.3 years, men = 154 (70%)] were enrolled. After 20 weeks treatment, systolic and diastolic weighted standard deviations were significantly lower in L/A group than L/H group. (Table) In multivariate regression analysis, significant difference of diastolic weighted standard deviation after 20 weeks treatment was independent of 24-hour SBP and DBP between two groups. Conclusions: ARB/calcium-channel blocker combination is more favorable in reduction of 24-hour BPV than ARB/diuretic combination independent of 24-hour BP differences. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Hypertension Seoul 2016 조직위원회 | - |
dc.title | ANGIOTENSIN II RECEPTOR BLOCKER COMBINED WITH CALCIUM CHANNEL BLOCKER IS MORE EFFECTIVE IN REDUCTION OF BLOOD PRESSURE VARIABILITY THAN COMBINED WITH DIURETICS | - |
dc.type | Conference | - |
dc.contributor.affiliatedAuthor | Shin, Jinho | - |
dc.identifier.wosid | 000440372403242 | - |
dc.identifier.bibliographicCitation | Hypertension Seoul 2016: The 26th Scientific Meeting of the International Society of Hypertension, pp.E517 | - |
dc.relation.isPartOf | Hypertension Seoul 2016: The 26th Scientific Meeting of the International Society of Hypertension | - |
dc.relation.isPartOf | ISH 2016 Abstract Book Supplement 1 | - |
dc.citation.title | Hypertension Seoul 2016: The 26th Scientific Meeting of the International Society of Hypertension | - |
dc.citation.startPage | E517 | - |
dc.citation.endPage | E517 | - |
dc.citation.conferencePlace | KO | - |
dc.citation.conferencePlace | 서울 코엑스 | - |
dc.citation.conferenceDate | 2016-09-24 | - |
dc.type.rims | CONF | - |
dc.description.journalClass | 1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.